|
Immunogen
|
FI-MCMV
|
ELISA titer (2n) of IgG antibodyb
|
Protection against SG-MCMV challenge
|
|---|
|
Dosage (μg)
|
Immunization once
|
Immunization twice
|
Spleen virus titers (log10PFU/ml)
|
Survival mice/tested mice
|
|---|
|
Adjuvant-free
|
0.25
|
3.67 ± 1.15
|
5.33 ± 0.58
|
5.27 ± 0.19
|
0/6
|
|
+ Chitosan
| |
5.00 ± 1.00
|
9.67 ± 1.15c
|
5.08 ± 0.13
|
0/6
|
|
+ Alum
| |
6.33 ± 1.53c
|
11.33 ± 1.15c
|
5.14 ± 0.11
|
0/6
|
|
+ MF59
| |
7.33 ± 0.58c
|
12.33 ± 1.53c
|
4.58 ± 0.36c,e
|
2/6
|
|
Adjuvant-free
|
1
|
4.67 ± 1.15
|
10.00 ± 1.73
|
5.13 ± 0.29
|
0/6
|
|
+ Chitosan
| |
6.33 ± 0.58
|
12.00 ± 1.00c
|
4.64 ± 0.50e
|
2/6
|
|
+ Alum
| |
7.33 ± 0.58c
|
12.33 ± 1.15c
|
4.78 ± 0.15e
|
1/6
|
|
+ MF59
| |
10.67 ± 1.15c,d
|
15.00 ± 1.00c,d
|
3.51 ± 0.49c,d,e
|
5/6e
|
|
Adjuvant-free
|
4
|
7.67 ± 0.58
|
11.67 ± 1.52
|
4.41 ± 0.48e
|
3/6
|
|
+ Chitosan
| |
10.00 ± 1.73c
|
13.67 ± 0.58c
|
4.02 ± 0.51e
|
5/6e
|
|
+ Alum
| |
10.33 ± 0.58c
|
14.00 ± 1.00c
|
3.80 ± 0.11c,e
|
6/6e
|
|
+ MF59
| |
11.67 ± 0.58c
|
16.33 ± 0.58c,d
|
2.56 ± 0.77c,d,e
|
6/6e
|
|
Chitosan only
|
-
|
Undetected
|
Undetected
|
5.87 ± 0.17
|
0/6
|
|
Alum only
| |
Undetected
|
Undetected
|
5.68 ± 0.27
|
0/6
|
|
MF59 only
| |
Undetected
|
Undetected
|
5.62 ± 0.38
|
0/6
|
|
Mock
| |
Undetected
|
Undetected
|
5.73 ± 0.34
|
0/6
|
|
PBS
| |
-
|
-
|
5.91 ± 0.39
|
0/6
|
-
aThe mice were immunized twice (3 weeks apart) with various doses of vaccine (0.25, 1, or 4 μg) with or without adjuvant (MF59, alum, or chitosan) by i.m. injection. Serum samples from immunized mice were obtained 3 weeks after the first and second immunization, respectively. Three weeks after immunization, all the mice were challenged with a lethal dose of SG-MCMV. Spleen virus titers 5 days after challenge and survival rates of mice 21 days post-infection were determined. Results are expressed as means ± SD of tested mice in each group.
-
bSerum samples were diluted by two-fold serial dilutions and “n” represents the dilution factor.
-
cSignificant difference (p < 0.05), compared with the corresponding adjuvant-free subjects.
-
dSignificant difference (p < 0.05), compared with the corresponding alum adjuvant subjects.
-
eSignificant difference (p < 0.05), compared with corresponding control subjects.
